Original ResearchPublished 9 October 2026Population cellular kinetics and exposure-CSR analysis of CAR-T cells in Chinese patients with relapsed/refractory B-ALLYicong Bian · Jinjie Yuan · Chenrong Huang · Kaijie Zhang · Ling Xue · Fan Xia · Liqing Kang · Yan Wang · Hua Zhang · Lei Yu · Depei Wu · Liyan MiaoFrontiers in Pharmacologydoi 10.3389/fphar.2026.1878984
Original ResearchPublished 16 September 2026Adoptive T Cell therapy for cancer and autoimmune disease: current advances, challenges, and future directionsQiu-Hong Bao · Angel Wu · Jianming Pang · Junwei Wang · Qingqing Chen · SuWen WuOncology Reviewsdoi 10.3389/or.2026.1905358
ReviewPublished 15 September 2026The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatmentAngel Alberto Justiz-Vaillant · Sachin Soodeen · Rodolfo Arozarena-Fundora · Patrick Eberechi Akpaka · Chandrashekhar UnakalFrontiers in Molecular Medicinedoi 10.3389/fmmed.2026.1931159
ReviewPublished 13 August 2026Functional genomics–guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and microenvironmental resistanceShiqi Cai · Yang Tan · Qian Yang · Juan HuangFrontiers in Genome Editingdoi 10.3389/fgeed.2026.1878460
ReviewPublished 2 July 2026CAR-T cell therapy in glioblastoma: from αβ to γδ T-cell platformsCostanza Dieli · Roberta Costanzo · Anna Maria Corsale · Federica Paolini · Marta Di Simone · Claudia Avellone · Francesco Dieli · Domenico Gerardo Iacopino · Salvatore Marchiafava · Rosario Maugeri · Serena MeravigliaOncology Reviewsdoi 10.3389/or.2026.1808229
ReviewPublished 11 November 2025A focus on LBCL patients in partial remission in the CAR-T eraGiuseppe Tarantini · Elena Arcuti · Caterina Buquicchio · Vera Carluccio · Gaetano De Santis · Candida Rosaria Germano · Mariangela Leo · Daria Carmela Loconte · Sonia Mallano · Rosanna Maria Miccolis · Teresa Maria Santeramo · Vanda Strafella · Vincenzo PavoneFrontiers in Hematologydoi 10.3389/frhem.2025.1675099
Molecular MedicinePublished 18 September 2024DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndromeGrace Haroun · Erlinda M. GordonFrontiers in Molecular Medicinedoi 10.3389/fmmed.2024.1461151
Molecular MedicinePublished 21 September 2023Elaborating the potential of Artificial Intelligence in automated CAR-T cell manufacturingNiklas Bäckel · Simon Hort · Tamás Kis · David F. Nettleton · Joseph R. Egan · John J. L. Jacobs · Dennis Grunert · Robert H. SchmittFrontiers in Molecular Medicinedoi 10.3389/fmmed.2023.1250508
